Merci, Nancy! Thank you very much for this and hope you are doing great.
You are right. Best way to avoid infection altogether. Even mild infection can lead to Long Covid.
Thanks, Eric.
Thank you!
I like this idea. Will explore feasibility.
I joined Dr. Susan Kuo from @longcovidcan-co.bsky.social to talk about Long COVID — what we've learned, where we are, and what's ahead.
youtu.be/T3WD-tTFSWQ
Thank you, Eric.
For your weekend reading: I wrote about what our BMJ findings mean for addiction — why GLP-1s work across every addictive substance, and how these drugs seem to quiet cravings the same way they quiet food noise.
@us.theconversation.com
theconversation.com/glp-1-drugs-...
there are adverse side effects too, and quite a bit of unknown. These are exciting results, but there is a lot more to learn.
Wrote about the implications in The Conversation
theconversation.com/glp-1-drugs-...
I wrote about the concept of "drug noise":
In STAT: www.statnews.com/2026/03/04/g...
These findings point to a common druggable biologic pathway across addictions. GLP-1 drugs may offer a fundamentally new approach—not targeting individual substances, but the shared neurobiology of craving itself. Randomized trials testing prevention and treatment of addiction are needed.
What's most striking is the breadth. One drug class, consistent effects across substances. That points to a shared biologic pathway: something I've been calling "drug noise"—the relentless craving that pulls people back to a substance, paralleling the "food noise" these drugs are known to quiet.
New in the BMJ: Our study of 600,000 people found GLP-1 drugs associated with 50% fewer substance-related deaths, 39% fewer overdoses, and reduced addiction risk across alcohol, opioids, cocaine, cannabis, and nicotine.
www.bmj.com/content/392/...
Please help us spread the word.
We are hiring postdoctoral fellows in Clinical Epidemiology and Pharmacoepidemiology.
Details and application via Indeed.
Honored to speak at Harvard’s Radcliffe Institute workshop on #LongCOVID. I am energized by our 2 days of brainstorming about the road ahead. The challenges are real, but I’m leaving hopeful. Millions living with Long Covid are counting on our progress—we must keep keep pushing forward!!!
This story gets wilder. One of the researchers who is helping design this new generation of addictive foods is on GLP-1!!!
Wild but true.
buff.ly/40QHDnk
For decades, the junk food industry has deliberately engineered foods to be addictive. GLP-1 drugs have helped people break free from this cycle. The industry is now searching for ways to undo the effects of these meds, aiming to design foods that remain addictive for those on GLP1. buff.ly/40QHDnk
GLP-1 drugs are revolutionizing the way we think about obesity. It is a chronic disease (like high blood pressure), and might actually be a form of food addiction. One reason these drugs are so effective in treating obesity could be that they address the underlying addiction.
New Long Covid policy paper from Norway outlines knowledge gaps and lessons learnt for developing preparedness for future pandemics.
Section 5 (pictured below) outlines their recommendations. Led by Sara Illman, PhD and colleagues.
www.nordforsk.org/2025/knowled...
Alzheimer, addictions, dépression… les effets bénéfiques de l’Ozempic et des médicaments apparentés
My Ozempic piece has been translated into French; thanks the amazing team at Conversation in Paris. @theconversation.com @france.theconversation.com
theconversation.com/alzheimer-ad...
I talked to Dani Blum from @nytimes.com about the potential role of GLP-1 drugs (Ozepmic and similar drugs) on Alzheimer’s disease.
They seem promising, but more data is needed.
www.nytimes.com/2025/01/31/w...
🚨 ICYMI: Our latest study shows that the popular GLP-1 weight loss drugs (e.g. Ozempic) have broad health benefits — reducing risks of 42 health conditions. They are not without risks — increasing risks of of 19 health conditions.
www.nature.com/articles/s41...
📄 Free access to the full study: rdcu.be/d6VYU
New from my team: In a study of over 2 million people, we comprehensively mapped the benefits and risks of GLP-1 (e.g. Ozempic and similar weight loss drugs) across 175 health conditions.
Please share and download before it goes back behind paywall.
Happy to do it. Reach out by email please (Gmail).
Thanks to Kristina Sauerwein for the press release and Abeeha Shamshad and Jessica Church for media outreach
Thanks to our reviewers, editors and all those supported us.
Link to press release medicine.washu.edu/news/study-i...
A lot of people who would benefit from GLP1 are not able to access them due to cost. Access issues to these meds should be solved.
www.nature.com/articles/s41...
While I am enthusiastic about the potential for GLP1 meds in helping address the obesity epidemic, prevention must remain the foundation of our approach to health and well-being.
www.nature.com/articles/s41...
